Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients

Jose Antonio Vazquez, S. Gupta, A. Villanueva

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.

Original languageEnglish (US)
Pages (from-to)781-783
Number of pages3
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume17
Issue number11
DOIs
StatePublished - Dec 1 1998
Externally publishedYes

Fingerprint

Candidiasis
Granulocyte-Macrophage Colony-Stimulating Factor
Acquired Immunodeficiency Syndrome
Amphotericin B
Azoles
Fluconazole
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

@article{8c942477728640f39e82f1e2ba2213a6,
title = "Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients",
abstract = "The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.",
author = "Vazquez, {Jose Antonio} and S. Gupta and A. Villanueva",
year = "1998",
month = "12",
day = "1",
doi = "10.1007/s100960050185",
language = "English (US)",
volume = "17",
pages = "781--783",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Vieweg",
number = "11",

}

TY - JOUR

T1 - Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients

AU - Vazquez, Jose Antonio

AU - Gupta, S.

AU - Villanueva, A.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.

AB - The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.

UR - http://www.scopus.com/inward/record.url?scp=0032440451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032440451&partnerID=8YFLogxK

U2 - 10.1007/s100960050185

DO - 10.1007/s100960050185

M3 - Article

VL - 17

SP - 781

EP - 783

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 11

ER -